HLA
RNAM

Hamilton Lane Advisors’s Avidity Biosciences RNAM Stock Holding History

Hamilton Lane Advisors’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-31,442
Closed -$802K – 80
2020
Q4 		$802K Buy
+31,442
New +$917K 0.3% 38

Other funds holding RNAM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hamilton Lane Advisors's RNAM Position: Q1 2021 in Review

Hamilton Lane Advisors sold out of Avidity Biosciences (RNAM) in Q1 2021, closing a stake of 31,442 shares — an estimated $802K sold.

Hamilton Lane Advisors first reported a position in RNAM in Q4 2020 and held it in 1 quarter. The position peaked at $802K in Q4 2020. 100 funds tracked by Wall St. Rank hold RNAM as of Q1 2021.

  • Hamilton Lane Advisors reported no remaining Avidity Biosciences position as of Q1 2021 after selling out during the quarter.
  • Hamilton Lane Advisors sold 31,442 Avidity Biosciences shares in Q1 2021, an estimated $802K.
  • Hamilton Lane Advisors first reported a position in Avidity Biosciences in Q4 2020 and held it in 1 quarter.
  • Hamilton Lane Advisors's Avidity Biosciences position peaked at $802K in Q4 2020.
  • 100 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2021.

Based on Hamilton Lane Advisors's 13F filing for Q1 2021, filed 13 Apr 2021.